IL-4 and IL-13 Induce Protection of Porcine Endothelial Cells from Killing by Human Complement and from Apoptosis through Activation of a Phosphatidylinositide 3-Kinase/Akt Pathway1

Vascular endothelial cells (EC) perform critical functions that require a balance of cell survival and cell death. EC death by apoptosis and EC activation and injury by the membrane attack complex of complement are important mechanisms in atherosclerosis and organ graft rejection. Although the effects of various cytokines on EC apoptosis have been studied, little is known about their effects on complement-mediated EC injury. Therefore, we studied the abilities of various cytokines to induce protection of porcine aortic EC against apoptosis and killing by human complement, a model of pig-to-human xenotransplantation. We found that porcine EC incubated with IL-4 or IL-13, but not with IL-10 or IL-11, became protected from killing by complement and apoptosis induced by TNF-α plus cycloheximide. Maximal protection required 10 ng/ml IL-4 or IL-13, developed progressively from 12 to 72 h of incubation, and lasted 48–72 h after cytokine removal. Protection from complement was not associated with reduced complement activation, C9 binding, or changes in CD59 expression. Inhibition of PI3K prevented development of protection; however, inhibition of p38 MAPK or p42/44 MAPK had no effect. IL-4 and IL-13 induced rapid phosphorylation of Akt. Although protection was inhibited by an Akt inhibitor and a dominant negative Akt mutant transduced into EC, it was induced by transduction of EC with the constitutively active Akt variant, myristylated Akt. We conclude that IL-4 and IL-13 can induce protection of porcine EC against killing by apoptosis and human complement through activation of the PI3K/Akt signaling pathway.

[1]  S. Miyagawa [Complement regulatory proteins]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[2]  Ju-Hyun Kim,et al.  RANKL regulates endothelial cell survival through the phosphatidylinositol 3′‐kinase/Akt signal transduction pathway , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  T. Takano,et al.  p38 mitogen-activated protein kinase protects glomerular epithelial cells from complement-mediated cell injury. , 2003, American journal of physiology. Renal physiology.

[4]  A. Dalmasso,et al.  Characteristics of CD59 up‐regulation induced in porcine endothelial cells by αGal ligation and its association with protection from complement , 2003, Xenotransplantation.

[5]  Achsah D. Keegan,et al.  Interleukin-4 and Interleukin-13 Signaling Connections Maps , 2003, Science.

[6]  Tamar Geiger,et al.  Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. , 2002, Biochemistry.

[7]  I. T. Ten Berge,et al.  Role of complement in graft rejection after organ transplantation. , 2002, Transfusion medicine reviews.

[8]  B. van de Water,et al.  The membrane attack complex of complement induces caspase activation and apoptosis , 2002, European journal of immunology.

[9]  H. Rus,et al.  C5b-9 Terminal Complement Complex Protects Oligodendrocytes from Death by Regulating Bad Through Phosphatidylinositol 3-Kinase/Akt Pathway1 , 2001, The Journal of Immunology.

[10]  Zvi Fuks,et al.  Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice , 2001, Science.

[11]  Z. Fishelson,et al.  Involvement of the ERK mitogen‐activated protein kinase in cell resistance to complement‐mediated lysis , 2001, Clinical and experimental immunology.

[12]  P. Evans,et al.  Interleukin-13 protects endothelial cells from apoptosis and activation: association with the protective genes A20 and A1. , 2000, Transplantation.

[13]  J. Pober,et al.  A Phosphatidylinositol 3-Kinase/Akt Pathway, Activated by Tumor Necrosis Factor or Interleukin-1, Inhibits Apoptosis but Does Not Activate NFκB in Human Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[14]  W. Sessa,et al.  Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. , 2000, Circulation research.

[15]  J. Pober,et al.  IL-11 Activates Human Endothelial Cells to Resist Immune-Mediated Injury , 2000, The Journal of Immunology.

[16]  A. Dalmasso,et al.  Resistance Against the Membrane Attack Complex of Complement Induced in Porcine Endothelial Cells with a Galα(1–3)Gal Binding Lectin: Up-Regulation of CD59 Expression1 , 2000, The Journal of Immunology.

[17]  D. Haskard,et al.  TNF-α, IL-4, and IFN-γ Regulate Differential Expression of P- and E-Selectin Expression by Porcine Aortic Endothelial Cells1 , 2000, The Journal of Immunology.

[18]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[19]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[20]  Y. Fujio,et al.  Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner* , 1999, The Journal of Biological Chemistry.

[21]  T. Badea,et al.  Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. , 1999, Atherosclerosis.

[22]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[23]  J. Volanakis The human complement system in health and disease , 1998 .

[24]  J. Platt,et al.  Endothelial Cell Responses to Complement Activation , 1998 .

[25]  N. Christou,et al.  Endothelial Cells: Role in Infection and Inflammation , 1998, World Journal of Surgery.

[26]  J. Beranek Apoptosis is the main mechanism of cardiomyocyte death in the hyperacute rejection of heart xeno- and allografts. , 1997, Transplantation.

[27]  D. Candinas,et al.  Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment , 1997, Nature Medicine.

[28]  C. Stocker,et al.  In vitro accommodation of immortalized porcine endothelial cells: resistance to complement mediated lysis and down-regulation of VCAM expression induced by low concentrations of polyclonal human IgG antipig antibodies. , 1996, Transplantation.

[29]  B. Benson,et al.  Human IgM xenoreactive natural antibodies can induce resistance of porcine endothelial cells to complement‐mediated injury , 1996 .

[30]  M. Peterson,et al.  Induction of Endothelial Cell Apoptosis by TNFα: Modulation by Inhibitors of Protein Synthesis , 1994 .

[31]  J. Halperin,et al.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells , 1994, The Journal of experimental medicine.

[32]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[33]  C. Löwik,et al.  Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red. , 1993, Analytical biochemistry.

[34]  Z. Fishelson,et al.  Sublytic complement attack protects tumor cells from lytic doses of antibody and complement , 1992, European journal of immunology.

[35]  M. Shin,et al.  Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. , 1990, Journal of immunology.

[36]  B. Morgan Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. , 1989, The Biochemical journal.

[37]  A. Michael,et al.  Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. , 1983, The Journal of clinical investigation.

[38]  J. Platt,et al.  Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. , 1992, The American journal of pathology.

[39]  J. Platt,et al.  Transplantation of discordant xenografts: a review of progress. , 1990, Immunology today.